Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Novo Nordisk eyes IPO for its IT subsidiary, taps new CFO to lead review

Strategic reviews, sales and spinoffs are trendy in Big Pharma these days. Now, the Danish drugmaker Novo Nordisk has joined the bunch. Novo says it's weighing an initial public offering for its IT subsidiary, NNIT, and has hired a new CFO for the unit to handle the review.

Roche picks a new R&D boss as Barron ships out for Google

Roche didn't waste much time in replacing former R&D guru Hal Barron, tapping oncology head Sandra Horning to serve as its next chief medical officer and head of global product development.

Novartis Oncology chief Hoppenot leaps to the CEO job at partner Incyte

Novartis is saying goodbye to the man who steered its cancer business. Hervé Hoppenot, president of Novartis Oncology, has jumped ship for the CEO job at Incyte, one of the Swiss drugmaker's longtime development partners.

C-suite shuffle: Amgen CFO Peacock resigns

The company named Michael Kelly, an 11-year Amgen veteran, to hold the CFO position on an interim basis.

Teva chooses Erez Vigodman as new CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Former Bristol-Myers R&D chief signs on at VC firm

Sigal is joining New Enterprise Associates, where former MedImmune CEO David Mott has been leading the healthcare crew.

With CEO pick, Teva bets turnaround savvy will trump pharma know-how

Departed CEO Jeremy Levin officially has a successor at Teva Pharmaceutical Industries. As predicted, Erez Vigodman will step into the helmsman's role as of Feb. 11, while interim CEO Eyal Desheh will return to his previous position as CFO, the company said Thursday.

WSJ: Teva close to CEO choice, with acting CEO and ex-Actavis chief still up for the job

Teva Pharmaceutical Industries is said to be close to choosing Israeli executive Erez Vigodman to take its empty CEO chair, but as the Wall Street Journal reports, some other candidates are still in the running.

Just as hep C star Sovaldi makes its debut, Gilead commercial chief says he'll retire

Gilead Sciences just rolled out its much-anticipated hepatitis C treatment Sovaldi (sofosbuvir) last month. Now, the company's commercial chief is saying sayonara. EVP Kevin Young will retire Feb. 4, leaving his team to soldier on alone with the Sovaldi launch.

Rebel Teva shareholder throws his support to presumptive CEO Vigodman

Balky Teva shareholder Benny Landa has fallen in line behind the company's apparent choice for CEO, Erez Vigodman. As the Financial Times reports, Landa is once again circulating an email to fellow major shareholders--but this time to support the company's board rather than attack it.